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Abstract
Peripheral sensitization indicates increased responsiveness and reduced thresh-
old of nociceptive neurons in the periphery to the stimulation, which usually occurs 
after peripheral tissue injury and inflammation. As an integral part of pain, periph-
eral sensitization and its mechanisms have received much attention, and numerous 
types of neurotransmitters and chemicals related to peripheral sensitization were 
investigated. We developed an animal model of peripheral sensitization, and it 
provides evidence that some neurotransmitters, such as glutamate and substance P, 
release from adjacent peripheral nerves contributing to the peripheral sensitization 
of pathological pain. In this chapter, we reviewed the advances in peripheral sensi-
tization, and it will provide a basis for new targets to attenuate pain of peripheral 
origin.
Keywords: pain, peripheral sensitization, tissue injury, inflammation, 
neurotransmitter, ion channel
1. Introduction
Peripheral sensitization refers to reduced threshold and augmented response of 
the sensory nerve fibers in the peripheral to external stimulus, which is manifested 
as enhanced stimulus-dependent pain called primary hyperalgesia [1]. Commonly, 
peripheral sensitization occurs following peripheral nerve injury, tissue injury, and 
inflammation. Tissue injury may accompany the injury of peripheral nerve endings 
to some content. The endogenous chemicals released from the site of tissue injury or 
inflammation can activate and sensitize the peripheral sensory neurons, resulting 
in peripheral sensitization [2, 3]. Similar sensitization phenomenon taking place 
in the central nervous system is called central sensitization, which may be initially 
induced by peripheral sensitization [4, 5]. The peripheral sensitization and central 
sensitization together produce neuropathic pain and inflammatory pain reflected 
as allodynia and hyperalgesia. However, there is no satisfactory therapy for the 
management of allodynia and hyperalgesia.
Peripheral sensitization increases the release of the neurotransmitters from the 
peripheral endings and the terminals of the spinal cord, aggravating the neurogenic 
inflammation and nociception. Pain usually starts with the activation of peripheral 
sensory neurons which subsequently process and convey nociceptive message to 
spinal cord and brain regions. That is, to some extent, the inhibition of peripheral 
sensitization may prevent the subsequent central events. For the pain management, 
local drug delivery can focus on the specific peripheral mechanisms including 
transduction and transmission of nociceptive signaling to limit both peripheral and 
central sensitization processes [6]. These facts increase the necessity to investigate 
the exclusive mechanisms of peripheral sensitization. Thus, in this chapter, we 
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focus on the advances in peripheral sensitization, and it may contribute to the 
improvements of new therapies relieving pain of peripheral origin.
2. Peripheral nociceptors
Nociception is a process that different stimuli (thermal, mechanical, and 
chemical) are detected by the peripheral nerve fibers called nociceptor, through 
which the noxious stimuli are transduced into action potentials and conducted 
to the spinal cord and brain [7]. Unlike other sensory modalities that respond 
to innocuous stimulus such as touch, nociceptors are only activated by noxious 
stimuli that could be harmful to the organism. The nociceptor consists of three 
parts: the axon, cell body, and central terminals. The cell bodies of the nocicep-
tors are located in the dorsal root ganglia (DRG) for the body and the trigeminal 
ganglia (TG) for the maxillofacial region, and they are always connected to the 
afferent fibers. The site where the terminals of the fibers respond to peripheral 
stimuli is known as the receptive field. According to the type of the afferent 
fibers, the nociceptor can be divided into myelinated Aδ fibers and unmyelinated 
C fibers. Many of the unmyelinated fibers respond to a wide range of noxious 
stimuli [8]. Nociceptors can send and receive the messages from both the central 
and peripheral terminals [5, 7]. Following injury and inflammation, the nocicep-
tors may become sensitized by pro-nociceptive mediators, such as prostaglandins, 
bradykinin, substance P (SP), extracellular ATP, and protons [9]. The activation 
of the nociceptors is related to the site of the stimuli application and stimuli 
modality including chemical, thermal (hot and cold), and mechanical modalities 
[8]. Several changes in nociceptors may account for the peripheral sensitization. 
First, the thresholds of primary afferent Aδ and C fibers lower in response to 
innoxious stimuli. Second, Aδ and C fibers at the site of tissue injury or inflam-
mation exhibit enhanced responses to supra-threshold mechanical or heat stimuli. 
Third, adjacent receptive fields of Aδ and C fibers increase innervation to the 
injured site [10].
3. Challenges in developing effective drugs
Although considerable progress has been made in investigating the role of 
peripheral sensitization in nociceptive processing during the past decades, pain 
researches bear burdens in translation from pre-clinical studies to successful clini-
cal intervention. Several reasons may explain why the effective analgesics develop 
slowly. First, the complicated mechanisms of different patients in distinct pain 
states and the diversity types and functions of mediators in different pain path-
ways may be barriers in developing effective therapies [7, 11]. Second, currently 
available analgesic drugs targeting pain mechanisms produce serious side-effects 
and unsatisfactory efficacy [2, 11, 12]. As is known to all, the most popular analge-
sia drug, opioid, is hampered by desirable side-effects such as tolerance, respira-
tory depression, and addiction [13, 14]. The transient receptor potential vanilloid 
1 (TRPV1) antagonists have side-effects such as loss of the noxious heat sensation, 
increased burn risk, and hyperthermia [15]. Obviously, these challenges drive us to 
find drugs targeting selectively on modulation of peripheral mechanisms and not 
crossing the blood-brain-barrier, through which the side-effects may be avoided. 
To reduce potential systemic side-effects and improve compliance, there is a 





Several animal models of various pain states have been established to investigate 
the mechanisms of peripheral sensitization, for example, inflammation pain models, 
neuropathic pain evoked by disease or damage to peripheral nerves, and post-operative 
pain models. Animal models of inflammatory pain have used a number of different 
irritants that are injected into skin, paw, muscle, joint, and visceral organ. Carrageenan, 
complete Freund’s adjuvant (CFA), and capsaicin are commonly used inflammatory 
irritants to induce hyperalgesia. Common nerve injury models include: (1) ligating or 
transecting the spinal nerves, such as spinal nerve ligation model (SNL); (2) ligating or 
lesioning the sciatic nerve, such as chronic constriction injury (CCI); and (3) ligating 
distal branches (peroneal and tibial) of the sciatic nerve (spared nerve injury) [16].
To better understand the mechanisms of transmission between peripheral 
sensory nerve endings, we have successfully established an electrophysiological 
animal model in which antidromic electrical stimulation of a sensory nerve excites 
the adjacent primary afferents from the different spinal segments [17]. In this model, 
two adjacent cutaneous branches of spinal dorsal rami in the thoracic segments, T9 
and T10, were dissociated and transected proximally from the spinal cord in anesthe-
tized rats. Then antidromic electrical stimulation with 0.5 ms pulse duration, 20 Hz 
frequency, and 1 mA intensity was applied to T9 spinal nerve branch, and the nerve 
activities of T10 nerve branch were recorded [18]. All recorded afferent neurons from 
the T10 cutaneous branch were classified as Aβ, Aδ, and C fibers according to the 
conduction velocity and the receptive properties [19]. The discharges of the isolated 
Aβ, Aδ, and C fibers of the T10 cutaneous branch were significantly enhanced by 
antidromic electrical stimulation of the adjacent T9 spinal nerve branch [18]. It is in 
line with our previous studies that antidromic stimulation of T9 spinal nerve branch 
can activate and sensitize Aβ, Aδ, and C fibers obtained from the adjacent T10 dorsal 
cutaneous branch [20–23]. The activation and sensitization of these fibers not only 
occur between the peripheral sensory nerve terminals, but also conduct nociceptive 
impulses to the central nerve system [17, 24]. The increase in neural discharges of the 
peripheral fibers caused by the electrical stimulation of adjacent cutaneous nerves 
mimicked the effects of released chemicals at the peripheral nerve endings [25]. 
On the basis of this model, the effects of antidromic electrical stimulation of spinal 
cutaneous branches on the discharge activities of remote mechanoreceptive units 
were observed. It was found that antidromic stimulation of either T8 or T9 dorsal 
cutaneous branch significantly increased the discharge activities of the remote T12 
nerve, and the increasing time after the electrical stimulation was delayed as the 
distance increased between the stimulated branch and the recorded one [26].
In these experiments, both nerve branches of the adjacent segments were iso-
lated from the central nervous system; the activation of nerve fibers at one segment 
by antidromic electrical stimulation affects an adjacent segment suggesting that 
electrical and chemical signals are transmitted from the stimulated nerves to the 
recorded fibers without any involvement of the central nervous system. Electrical 
stimulation of the nerve directly induces the release of chemicals; these chemicals 
and substances through diffusion produce afferent impulses of adjacent nerve 
endings and also cause release of neurotransmitters at the adjacent peripheral nerve 
endings, a process known as axon reflex [17, 23, 26, 27].
5. Mechanisms of peripheral sensitization
There are two processes implicated in peripheral sensitization: (1) early post-
translational changes in the peripheral terminals of nociceptors, for example, the 
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phosphorylation of the ion channels prolongs depolarization and enhances response 
by lowering the open threshold or prolonging the open time of channels; (2) altered 
gene expression, changing transcription or translation of certain protein [10, 28]. 
For instance, deletion or silencing of calcitonin gene-related peptide alpha (αCGRP) 
gene expression drastically reduces TRPV1 potentiation in peptidergic nociceptors 
by abrogating its Ca2+-dependent exocytotic recruitment [29].
Peripheral sensitization results from sensitization and excitation of the primary 
afferent neurons following tissue injury and inflammation. When a peripheral 
nerve is injured, the distal stump of injured axons undergoes Wallerian degenera-
tion, i.e., breakdown of myelin sheaths, recruitment of inflammatory cells from the 
circulation, and over-production of growth factors and pro-inflammatory cyto-
kines or mediators. These cytokines and mediators not only promote the regenera-
tion of injured axons but also activate and sensitize nociceptors [30]. During the 
process of sensitization, the inflammation mediators either bind to different recep-
tors or activate second messenger systems, resulting in the modification of the ion 
channels [31]. Primary targets of these mediators are ion channels; the activation of 
either the voltage-gated channel or the ligand-gated channel enhances the number 
of the action potentials, a process known as sensitization. A wide range of chemi-
cals, such as nerve growth factors (NGF), bradykinin, SP, prostaglandins, opioids, 
and glutamate, contribute to the peripheral sensitization (Figure 1). The following 
section will address inflammatory mediators, ion channels, and neurotransmitter 
receptors involved in peripheral sensitization.
6. Inflammatory mediator
Bradykinin and prostaglandin have attracted much attention among inflam-
matory mediators. The inflammatory mediator prostaglandin E2, released from 
the inflamed tissue surrounding the terminals of sensory neurons or from endo-
thelial cells after surgical trauma, contributes to the abnormal pain responses in 
Figure 1. 
After tissue injury, chemicals such as inflammatory mediators and neurotransmitters released from the injury 
site or the nerve endings activate the receptors and channels on the adjacent peripheral nerve terminals, 
subsequently resulting in peripheral sensitization. In our electrophysiological model, antidromic electrical 
stimulation of one nerve branch induces the release of neurotransmitters and modulators into the peripheral 
tissues to mimic tissue injury condition. The released chemicals diffuse to the adjacent peripheral nerve 
terminals and induce peripheral sensitization. Abbreviations: CGRP, calcitonin gene-related peptide; DRG, 
dorsal root ganglion; NGF, nerve growth factor; SP, substance P; SST, somatostatin.
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inflammation pain and neuropathic pain. Peripheral injection of nonselective and 
selective cyclooxygenase (COX) inhibitors attenuates neuropathic pain following 
partial sciatic nerve transection [32], indicating that pro-inflammatory prostaglan-
dins are involved in the development of neuropathic pain. Both morphological and 
pharmacological evidence indicate that peripheral prostaglandins are involved in 
the maintenance of neuropathic pain following nerve injury [30]. In a study using a 
thoracic muscle incision model to characterize post-operative pain-related behav-
iors, tissue prostaglandin E2 increased in surgery animals compared with the sham-
operated control animals under the same anesthesia, indicating that prostaglandin 
E2 is associated with post-operative pain [33]. Prostaglandin also participated in the 
long-lasting sensitization of nociceptors in acute inflammation induced by carra-
geenan in mice [34].
Bradykinin is an important neuropeptide released after tissue injury. Upon 
release, bradykinin affects nociceptive afferents through activation of two phar-
macologically distinctive receptors designated B2 and B1, respectively [35, 36]. 
An increased B1 receptor gene expression was found in peripheral neural tissue in 
CFA-induced mechanical hyperalgesia, and the selective bradykinin B1 receptor 
antagonist BI113823 reduced CFA-induced mechanical hyperalgesia [37]. Activation 
of bradykinin receptors promoted nociceptor sensitization and hyperalgesia by acti-
vating the protein kinase C (PKC) second-messenger system [38]. A study on CCI 
model showed that there was an increase in the mRNA expression of both B1 and B2 
receptors in lumbar DRG following CCI. Furthermore, pharmacological antagonists 
of these receptors alleviate pain hypersensitivity associated with nerve injury [39]. 
Bradykinin-mediated sensitization of heat responses in C mechanoheat-sensitive 
fibers of isolated rat skin-saphenous nerve was significantly attenuated by the 
COX-1 and COX-2 inhibitors [40].
7. Ion channels
The electrical activity of primary afferent neurons is primarily governed by the 
expression and function of ion channels that define the resting membrane poten-
tial, action potential initiation, depolarization and repolarization, refractory period 
between action potentials, and transmitter release from their terminals in the 
dorsal horn. In this part, we will review the voltage-gated channel transient recep-
tor potential vanilloid (TRPV), voltage-gated sodium channels, and voltage-gated 
calcium channels (VGCCs), which may be dysregulated underlying peripheral 
sensitization.
7.1 The voltage-gated channel transient receptor potential vanilloid
The TRPV is one of the subfamilies of the transient receptor potential (TRP) 
through which the external stimuli are transduced to electrical impulses. Based on 
amino acid sequence homology, members of this family in the mammalian have 
been classified into six subfamilies: TRPA (ankyrin), TRPV (vanilloid), TRPM 
(melastatin), TRPC (canonical), TRPP (polycystin), and TRPML (mucolipin) [41]. 
TRP channels are tetramers composed of identical subunits, which have six trans-
membrane domains and cytoplasmic amino and carboxy termini [42].
7.1.1 TRPV1
TRPV1 is a non-selective cation ion channel which is largely located in small-
diameter neurons with C fiber axons [43] in DRG innervating body and TG 
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innervating oral and maxillofacial regions. Similar to voltage-gated sodium chan-
nels, TRPV1 exhibits radial symmetry around a central ion channel which is formed 
by transmembrane segments 5–6 (S5–S6) and the intervening pore loop and is 
flanked by S1–S4 domains [42]. TRPV1 is a polymodal receptor which can be acti-
vated by a wide range of stimuli including capsaicin [44], other endogenous lipids, 
acidic pH [43], and noxious heat (>42°C) [44]. TRPV1 upregulation in sensory 
neurons is a key element in pain development and maintenance of several chronic 
pathological conditions. Recently, the abundance of the evidence suggests that the 
TRPV1 receptor is one of the key targets for developing new analgesics.
7.1.2 TRPV1 and pain
It is widely acknowledged that TRPV1 contributes to heat and mechanical 
sensitization. Injection of capsaicin into the skin in humans produces a burn-
ing sensation and flare response, the area of application becomes insensitive to 
mechanical and thermal stimulation, the area of flare exhibits a primary hyper-
algesia to mechanical and thermal stimuli, and an area beyond the flare exhibits 
secondary allodynia [45, 46]. Through the activation of TRPV1 by the capsaicin and 
other pungent compounds, burning pain may be produced via depolarizing specific 
subsets of Aδ and C nociceptors [44]. The TRPV1 population is also required for 
the development of thermal and mechanical hyperalgesia after CFA injection [47, 
48]. Knockout of TRPV1 or pretreatment with the TRPV1 antagonists, AMG9810 or 
5′-iodoresiniferatoxin (5′-IRTX), significantly reduced complement C5a-induced 
mechanical sensitization, indicating that TRPV1 activity is required for maintaining 
C5a-induced mechanical hypersensitivity [49]. The TRPV1 can assess the physiolog-
ical environment of the sensory nerve terminal and alter neuronal responsiveness in 
the context of tissue injury [43]. The mechanical allodynia and thermal hyperalge-
sia were alleviated in Pirt (a membrane protein which binds to TRPV1 to enhance its 
activity) knockout mice in CCI models, and the increase in TRPV1 expression was 
less in Pirt knockout mice in CCI models, suggesting that Pirt together with TRPV1 
is involved in CCI-induced neuropathic pain [50].
7.1.3 Activation of the TRPV1
The activation of TRPV1 increases the calcium permeability of the receptor, 
priming membrane depolarization and subsequent sensory neuron activation [44, 
51]. The TRPV1 receptor occupancy triggers Na+ and Ca2+ influx, action potential 
firing, and the consequent burning sensation associated with spicy food or capsa-
icin-induced pain [44]. TRPV1 can be sensitized via the second messenger signal-
ing cascade in response to various pro-inflammation mediators and chemicals like 
bradykinin, lipids, and prostaglandins [44]. A multitude of lipids modulate the 
TRP-channels through G-protein coupled receptor via different signaling pathways 
[52]. TRPV1 contributes to the persistence of remifentanil-induced both thermal 
and mechanical post-operative hyperalgesia through the trafficking of N-methyl-
D-aspartate (NMDA) receptors via the activation of calmodulin-dependent protein 
kinase (CaMKII)-PKC but not protein kinase A (PKA) signaling pathways in DRG 
neurons [53]. Bradykinin sensitizes TRPV1 through enhancing the excitability 
of the peptidergic C-type nociceptor end and the neuronal exocytosis of large 
dense core vesicles containing αCGRP [54]. Tumor necrosis factor-α (TNF-α) can 
sensitize TRPV1 by promoting its expression, thus leading to mechanical allodynia 
and thermal hyperalgesia in vincristine-treated rats [55]. NGF causes a long-lasting 
sensitization of nociceptor endings, in particular to thermal and chemical stimuli, 
which can be attributed to up-regulated TRPV-1 receptors in sensory endings [56].
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The phosphorylation of TRPV1 has been shown to cause sensitization of the 
channel. The first report of the co-expression pattern of two ligand-gated chan-
nels, TRPV1 and P2X3 in TG, demonstrating that pretreatment with αβ-meATP 
(a selective P2X3 agonist) results in phosphorylation and sensitization of TRPV1, 
thus contributes to the peripheral sensitization known to underlie masseter hyper-
algesia [57]. Activation of the metabotropic glutamate receptor (mGluR) 1/5 leads 
to phosphorylation of a specific TRPV1 residue via PKC and A-kinase–anchoring 
protein (AKAP) 150 in trigeminal sensory neurons, and functional interactions 
between glutamate receptors and TRPV1 mediate mechanical hyperalgesia in the 
muscle tissue [58]. A recent study found that the temperature sensitivity of TRPV1 
channels are enhanced by SUMOylation of TRPV1 protein at a C-terminal Lys 
residue, indicating that SUMOylation of TRPV1 is essential for the key mechanism 
underlying peripheral sensitization and the development of inflammatory thermal 
hyperalgesia [59].
7.1.4 Other TRP receptors
Sensory neurons also express other TRP receptors besides TRPV1. TRPA1 is 
initiated by noxious cold (17°C), natural oils such as cinnamaldehyde and mustard 
oil, and inflammatory mediators [60]. TRPA1 is demonstrated to be cold sensitive 
[61] and plays roles in both cold transduction and mechanotransduction in cutane-
ous sensory neurons. AKAP 79/150 facilitates phosphorylation and sensitization of 
TRPA1 in peripheral sensory neurons, resulting in persistent mechanical hypersen-
sitivity [62]. Another study also indicated that TRPA1 activation could co-sensitize 
TRPV1 channels [60]. Similar to TRPV1, TRPM8 is temperature sensitive and 
partly expressed by the somatosensory neurons in the DRG and TG. TRPM8 is 
activated by cool/cold temperature starting in the innocuous range (18–23°C) and 
cooling compounds such as menthol and icilin [63]. TRPV3 and TRPV4 have also 
been cloned and are heat sensors. TRPV3 was found to be responsible for detecting 
innocuous warm temperature ranging from 31 to 39°C. TRPV3 knockout mice had 
strong deficit in response to innocuous heat sensitivity but not in other sensory 
modalities [64]. TRPV4, which is expressed in small or medium diameter neurons 
with overlap in expression with TRPV1 [65], is activated by phorbol ester, innocu-
ous temperature with a threshold higher than 27°C, low pH, citrate, endocan-
nabinoids, arachidonic acid metabolites, and nitric oxide (NO) [66]. The evidence 
showed that TRPV4 was implicated in the transduction of mechanical stimuli and 
the development of mechanical hyperalgesia [3].
7.2 The voltage-gated sodium channel
Voltage-gated sodium ion channels are integral membrane proteins compris-
ing a pore-forming α-subunit and two accessory β-subunits [67]. To date, nine 
isoforms of α subunit voltage-gated sodium channel (Nav1.1–1.9), which display 
various channel properties and selective tissue distribution, have been discovered. 
A variety of voltage-gated sodium channels are expressed in somatosensory neu-
rons, including the tetrodotoxin-sensitive (TTX-S) channels Nav1.1, 1.6 and 1.7 and 
the tetrodotoxin-resistant (TTX-R) channels Nav1.8 and 1.9. Voltage-gated sodium 
channels are essential for the generation and conductance of action potentials and 
therefore a crucial factor in neuronal excitability. The functions of voltage-gated 
sodium ion channels are regulated by their expression level, channel properties, and 
subcellular distribution. If some drugs block sodium-channels, the conduction of 
action potentials will be prevented, for instance, the local anesthetics can be used 
to abolish pain due to blocking sodium channels. Acting as a broad acting sodium 
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blocker, phenytoin may inhibit overactivities of small fibers and reduce pain in 
small fiber neuropathic pain and diabetic neuropathic pain [68].
7.2.1 Nav1.7
Nav1.7 is of high interest because it functions as a kind of non-opioid analgesics. 
Nav1.7, encoded by a sodium channel voltage-gated IX alpha subunit gene (SCN9A), 
is highly enriched within DRG and TG peripheral sensory neurons, as well as 
sympathetic neurons and olfactory epithelia [67, 69]. In rodent, Nav1.7 is expressed 
within the soma of small-diameter DRG neurons and along the peripheral and 
central C fibers from these cells [70]. However, it was found that human DRG had 
a high ratio of Nav1.7 expression and low ratio of Nav1.8 expression compared to 
mouse DRG, indicating that Nav1.7 mRNA predominantly expressed voltage-gated 
sodium channels in human DRG tissue [71]. Expression of Nav1.7 is also detected 
in the preterminal central branches and terminals in the dorsal horn, as well as at 
nodes of Ranvier in a subpopulation of small-diameter myelinated fibers [72].
7.2.2 Nav1.7 and pain
Nav1.7 serves a remarkable function in pain perception. The Nav1.7 knockout 
animals lose acute noxious mechanical sensation and inflammatory pain [73]. Mice 
lacking Nav1.7 in sensory neurons showed reduced hypersensitivity to selected neu-
ropathic pain and inflammatory pain models [74]. It has been found that injection of 
carrageenan increases expression of Nav1.3 and Nav1.7 and TTX-S currents in DRG 
neurons [75]. Estradiol upregulates TG Nav1.7 mRNA and protein expression, thus 
inducing sex-differences of nociception in temporomandibular disorders (TMD) 
and hyperalgesia of the inflamed temporomandibular joint (TMJ)[75]. Besides, 
Nav1.7 may interact with other signaling systems, such as endogenous opioids which 
are upregulated in the absence of Nav1.7 and thought to feedback onto DRG neurons 
and/or terminals to suppress their excitability [76]. The qPCR analysis revealed 
a significant and dose-dependent increase in Nav1.7 mRNA expression after the 
treatment of paclitaxel, which is a widely used chemotherapeutic drug that induces 
neuropathy and neuropathic pain, and the transient Na+ currents and action poten-
tial firing frequency in small-diameter human DRG neurons also increased [71].
7.2.3 SCN9A genes and Nav1.7
Recently, the mechanisms underlying several human pain disorders have 
been identified to be related to inherited mutations in the sodium channel genes 
expressed in damage-sensing neurons. The Nav1.7 is encoded by the SCN9A gene. 
Inherited primary erythromelalgia is resulted from mutations of the SCN9A gene, 
which causes a significant hyperpolarizing shift in voltage dependence of activa-
tion, facilitates channel opening, and increases the amplitude of current produced 
by Nav1.7. Small fiber neuropathy (SFN) is a typical pain disorder with burning 
pain throughout the body, in which electrophysiological analysis of Nav1.7 chan-
nels showed impaired slow inactivation, depolarized fast and slow inactivation, or 
enhanced resurgent currents [72]. By contrast, Nav1.7 function mutations in human 
cause congenital inability to experience pain [77].
7.3 The voltage-gated calcium channel
The VGCCs are a family of membrane proteins which control the influx of 
calcium ions that trigger neurotransmitter release in response to the depolarization 
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of the presynaptic cell membrane. Calcium ions can not only alter membrane 
potential but also serve as important signaling entities [78]. VGCCs are expressed 
on virtually all excitable cells, and their activity is critical for neurotransmitters 
release, the regulation of neuronal excitability, and intracellular changes including 
gene induction [79]. VGCCs are classified into high voltage-activated (HVA) or low 
voltage-activated (LVA) channels based on their voltage dependence of activation 
[80]. HVA channels are subdivided further based on their pharmacological and 
biophysical characteristics into L (Cav1.1–1.3), N (Cav2.2), P/Q (Cav2.1), and R-type 
(Cav2.3) [81], and LVA channels are known as T-type channels. HVA channels are 
complexes of a pore-forming α1 subunit, a transmembrane disulfide-linked com-
plex of α2 and δ subunits, an intracellular β subunit, and in some cases a trans-
membrane γ subunit [82], while T-type calcium channels are formed by a single α1 
subunit [83]. These different subtypes of HVA and LVA channels correspond to ten 
different α1 subunits, three of which termed Cav1, Cav2, and Cav3 are key determi-
nants of calcium channel subtype [84]. These channels are established and clinically 
validated drug targets for pain, and their roles and contributions to pain transmis-
sion have been extensively reviewed [85].
7.3.1 T-type calcium channels
T-type calcium channel family includes three subtypes, namely, Cav3.1, Cav3.2, 
and Cav3.3. T-currents have a unique function in neuronal excitability. In compari-
son with HVA channels, T-type calcium channels can activate at much more negative 
membrane potentials, inactivate rapidly, deactivate slowly, have small single-
channel conductance, and are insensitive to calcium ion antagonist drugs [82]. The 
large T-type currents are essential for light touch perception, long-term potentiation 
of synaptic transmission between nociceptive primary afferents, and superficial 
laminae SP-sensitive neurons of the dorsal horn [86, 87]. Reverse transcription 
(RT)–PCR and in situ hybridization analyses have shown that the most abundant 
T-type channels, Cav3.2, are expressed in small- and medium-diameter primary 
afferent neurons as well as neurons from the superficial laminae of the dorsal horn 
[88]. These Cav3.2 T-type channels in primary nociceptors are important regulators 
of afferent fiber excitability and contribute to peripheral sensitization [89].
7.3.2 Cav3.2 T-type calcium channels
The Cav3.2 subtype is a particularly attractive analgesic target. An increase in 
CaV3.2 T-type currents is associated with decreased nociceptive threshold, whereas 
inhibition of Cav3.2 channel activity mediates pain relief [90, 91]. A study indicated 
that intrathecal injection of Cav3.2 antisense oligonucleotide but not Cav3.1 or Cav3.3 
antisense oligonucleotide resulted in about an 80% decrease in T-type calcium cur-
rents in DRG neurons, and only Cav3.2 antisense treatment attenuated nocifensive 
responses in both naïve and neuropathic pain rats [92]. Several studies validated 
the potential utility of blocking Cav3.2 T-type calcium channels to reduce nocicep-
tion. For example, in a rat model of paclitaxel-induced peripheral neuropathy, 
T-type current amplitudes and density in DRG neurons were increased at day 7 after 
paclitaxel treatment and this was prevented by pretreatment of the specific Cav3.2 
T-type calcium channel inhibitor ML218 hydrochloride [93]. Selective inhibition of 
Cav3.2 channels reversed hyperexcitability of peripheral nociceptors and alleviated 
thermal and mechanical hypersensitivity in rodent model of postsurgical pain [94]. 
However, Cav3.2 knock-out mice showed reduced sensitivity to noxious pain but not 
chronic neuropathic pain [95], which contrasts with the potent analgesic actions 
of intrathecally delivered Cav3.2 channel blockers in neuropathic pain models, 
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suggesting that there is compensation from other types of calcium channels in the 
afferent fibers of Cav3.2 null mice that maintain pain transmission [96].
7.3.3 Other calcium channels
Primary afferent neurons express multiple types of VGCCs, P-, N-, L-, R-, 
T-type, and ancillary α2δ calcium channels have been most extensively studied with 
regard to chronic pain. N-type calcium channels are enriched at presynaptic nerve 
terminals where they trigger the release of neurotransmitters [97, 98], and inhibit-
ing N-type channel activity results in reduced neurotransmission and thus analgesia 
[99, 100]. Moreover, Cav2.2 channel knock-out mice decreased pain responses in 
neuropathic and inflammatory pain [101–104]. Besides N-type channels, blockade 
of L-type and P/Q-type can also prevent and/or attenuate subjective pain as well as 
primary and/or secondary hyperalgesia and allodynia in a variety of experimental 
and clinical conditions [105].
The Cav α2δ subunit is an important accessory subunit for all HVA calcium chan-
nels, and numerous studies point to an important role of α2δ in neuropathic pain. 
The α2δ-1 mRNA and protein levels are dramatically up-regulated in DRG in several 
models of neuropathic pain [79], and this increase in α2δ-1 correlates with the onset 
of allodynia [106, 107]. In clinical practice, the Cavα2δ subunit is the key pharmaco-
logical target for gabapentinoids (highly effective in the treatment of neuropathic 
pain) such as gabapentin and pregabalin [108, 109].
8. Neurotransmitters and receptors
8.1 G-protein coupled receptors
G-protein coupled receptor (GPCR) plays an important role in peripheral 
sensitization. The heterotrimeric GPCRs are the largest, most diverse recep-
tor families in the mammalian cells. GPCRs are integral membrane signaling 
proteins characterized by a seven-transmembrane-segment architecture. Upon 
activation of GPCRs, GPCRs associate with distinct classes of heterotrimeric G 
proteins, composed of α-, β-, and γ-subunits, and molecular cloning has now 
defined 34 genes encoding G-proteins in humans, 17 encoding α-, 5 encod-
ing β-, and 12 encoding γ-subunits [110, 111]. According to the a-subunits, G 
proteins are classified into four major classes, namely, Gs, Gi/o, Gq/11, and G12/13. 
Stimulation of the Gs subfamily activates adenylyl cyclase whereas stimulation 
of the Gi subfamily leads to its inhibition. Stimulation of the Gq subfamily 
activates phospholipase C (PLC), and the G12 family is implicated in the regula-
tion of small GTP binding proteins [110].
Through Gα and Gβγ, GPCRs are able to communicate with ligand- and 
voltage-dependent ion channels in pain pathways [112], including the TRP chan-
nels, acid-sensing ion channels (ASICS), and ATP-gated P2X channels, as well as 
voltage-gated sodium, calcium, and potassium channels [113]. The voltage-gated 
ion channels are finely tuned by GPCR in excitable cells, and these channels are key 
molecular transducers of electrical activities, allowing calcium signaling into the 
cells in response to action potentials or subthreshold depolarizations [114].
In chronic pain conditions, inflammatory mediators released by peripheral 
tissues and immune cells in response to injury act at GPCRs to sensitize periph-




innocuous stimuli. GPCRs can block pain upon targeting opioid, cannabinoid, 
α2-adrenergic, muscarinic acetylcholine, GABA, Group II and III mGlu, and 
somatostatin receptors.
8.2 Glutamate
Glutamate is an important excitatory neurotransmitter in the nervous system. 
There are two classes of the receptors: ionotropic glutamate receptors (iGluRs) 
and mGluRs. iGluR is a ligand-gated ion channel, whose subtypes are named for 
the agonist that activates the receptors, including the NMDA, α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid (AMPA), and kainate receptors (KA) [115]. 
mGluRs contain eight subtypes of receptors and are divided into three groups: 
Group I mGluRs (mGluR1 and mGluR5) are coupled to phospholipase C, activate 
PKC, and release Ca2+ from intracellular stores; Group II mGluRs (mGluR2 and 
mGluR3) and group III mGluRs (mGluR4, mGluR6-8) inhibit adenylyl cyclase 
activity [116, 117]. Both group II and group III mGluRs are mainly localized on 
presynaptic terminals.
All subtypes of iGluRs are found on DRG cells and can be transported into central 
and peripheral terminals by afferent axons. Besides, mGluRs have been identified on 
peripheral primary afferent fibers and are involved in the processing of peripheral 
nociception [118]. The excitation of the primary afferent neuron increases glutamate 
release in the peripheral and central ends of primary afferent neurons [119].
8.2.1 Glutamate and pain
Peripherally applied NMDA and non-NMDA receptor antagonists attenuate or 
block nociceptive behaviors in several animal models of inflammation pain  
[120–122]. The fact that injection of NMDA into the masseter muscle potently 
excites muscle afferent fibers and that local application of NMDA receptor antago-
nists abolishes glutamate-evoked increase in afferent discharge suggests that 
activation of peripheral NMDA receptors plays an important role in excitation of 
muscle afferent fibers [123]. A study showed that injection of glutamate into human 
masseter and temporalis muscles evoked pain and it could be decreased by co-
injection of NMDA antagonist ketamine [124].
Glutamate not only plays an important role in nociception transmission, but also 
is involved in the inflammation pain and neuropathic pain. Glutamate levels and 
the number of glutamate receptors elevate during cutaneous or deep tissue inflam-
mation. Peripheral inflammation increases the proportions of both unmyelinated 
and myelinated nerves expressing iGluRs [125]. Local injection of either NMDA or 
non-NMDA receptor antagonist significantly reduces thermal hyperalgesia induced 
by injection of carrageenan into the hind paw or injection of the kaolin/carrageenan 
into the knee joint, but without affecting joint edema [120]. Activation of group II 
mGluRs by mGluR2/3 agonists induces analgesia in inflammatory and neuropathic 
pain models [126, 127]. Activation of Group II mGluRs suppresses prostaglandin 
E2-induced sensitization of TRPV1 calcium responses in mice [128]. CFA-induced 
nociceptive behaviors were significantly alleviated by administration of L-AP4, 
group III mGluR agonist, suggesting that group III mGluRs negatively regulate 
nociceptive behaviors and pain transmission by lessening neuronal firing rates at 
the peripheral nerve in inflammation [117]. Group I mGluR antagonists and group 
II/III mGluR agonists attenuated the enhanced nociception and noxious stimulus-
induced glutamate release in the spinal cord dorsal horn in rats of CCI model and 
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injection of CFA into hind paw, suggesting a possible mechanism for their anti-
hyperalgesic effects [129].
8.2.2 Ionotropic glutamate receptors
Neurochemical studies indicate that neurotransmitters diffuse across the 
synaptic cleft (synaptic transmission) as well as diffuse through the extracel-
lular space and affect nearby neurons (non-synaptic communication) in the 
central nervous system. This is confirmed in a study that the site of action for 
glutamate can be at the autologous or nearby nerve terminals, and activation of 
these receptors can lower the activation threshold and increase the excitability of 
primary afferents [130]. In our experiments [18], we set up repeated antidromic 
stimulation of T9 nerve branch and recorded the activities from T10 cutaneous 
nerve branch. Forty minutes after the first antidromic stimulation of the T9 nerve 
branch, either NMDA receptor antagonist dizocilpine maleate (MK-801) or non-
NMDA receptor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX) is injected 
subcutaneously to the receptive field of T10 cutaneous branch, and the enhanced 
spontaneous discharges in the T10 cutaneous branch caused by stimulation of the 
T9 nerve branch were significantly blocked. The results indicate that peripheral 
iGluRs are involved in the activation of peripheral nerves following the antidromic 
stimulation, and the released glutamate diffuses to the adjacent sensory nerves 
and activates the adjacent afferents by binding to glutamate receptors located on 
the nerve terminals. No significant difference was found in effects on the nerve 
activities between the NMDA and non-NMDA iGluR antagonists, and injection 
of saline did not produce any effect on the increased discharges of the recorded 
nerve branch. These results provide us evidence that glutamate may contribute to 
interactions between peripheral nerve terminals via non-synaptic communication 
[131]. Cao et al. [132] summarized the evidence that glutamate released from the 
non-synaptic communication contributes to the nociception in peripheral: (1) 
electrical stimulation of peripheral nerve can result in the release of glutamate 
into peripheral tissues; (2) NMDA, AMPA, and KA receptors localize on a large 
population of myelinated and unmyelinated sensory axons in the peripheral 
nerves; (3) primary afferents can be excited by the exogenous glutamate and 
endogenous glutamate; and (4) no synaptic contacts have been reported between 
two peripheral nerves using morphological approaches.
8.2.3 Glutamate interacts with other receptors
Glutamate receptors may interact with other neurotransmitter receptors in the 
peripheral to regulate nociception. A study found that peripheral glutamate recep-
tors and TRPV1 receptors may interact to modulate the peripheral sensitization in 
some deep craniofacial nociceptive afferents [133]. CaMKII, which is persistently 
activated after NMDA receptor stimulation and phosphorylation of TRPV1, is likely 
to mediate the interactions between peripheral NMDA and TRPV1 receptors [134]. 
Glutamate, SP, and CGRP together contribute to the heat hyperalgesia combined 
with inflammation in the TRPV1-Cre mice [135]. There was a novel concept that 
tramadol acts as an agonist of TRPV1 [136] and local administration of tramadol 
blocked the paw licking (nociceptive behavior) in mice induced by glutamate [137].
A few studies on interactions between glutamate and opioid in the periphery 
have been conducted. A behavioral study has demonstrated that local cutaneous 
injection of DAMGO, a μ-opioid ligand, ameliorates the nociceptive behaviors 
caused by local injection of glutamate [138]. Our previous study demonstrated 




responses of Aδ and C fibers in the rat hairy skin, and this effect was reversed by 
pretreatment with the opioid receptor antagonist naloxone, suggesting that the 
effect of morphine on glutamate-evoked activities is mediated through activation of 
opioid receptors on the peripheral terminals of sensory neurons [139]. Glutamate is 
released from small diameter afferent fibers by heat stimulation in the periphery or 
local application of capsaicin, and the glutamate release is regulated by activation of 
opioid receptors on the peripheral endings of small-diameter afferent fibers [140].
Injection of SP significantly increases the afferent discharge of peripheral sen-
sory nerve endings [25]. A radioimmunoassay study showed that SP contents in the 
skin and tissues increased after electroacupuncture [141], indicating that SP plays 
a direct role in the stimulation of skin sensory nerve endings. Our previous study 
provided electrophysiological evidence for an interaction between SP receptor 
and glutamate receptor on the fine fiber activities in rat hairy skin, which may be 
involved in the mechanisms of hyperalgesia. Sub-threshold doses of SP (1 μmol/L, 
10 μL) injected subcutaneously into the dorsal hairy skin had no effect on the 
afferent discharges of either Aδ or C units, while local injection of the submaximal 
doses of glutamate (10 μmol/L, 10 μL) into the receptive fields increased the affer-
ent discharges of 35% (11/31) of Aδ fibers and 33% (6/18) of C fibers. In addition, 
glutamate-induced excitatory response was significantly enhanced by coinjection 
of subthreshold doses of SP [142]. Effects of glutamate and SP on spinal dorsal horn 
neurons may result from co-release of these two mediators from the same dorsal 
root afferent terminals [143].
8.3 Opioid
8.3.1 Opioid receptors
Peripheral nerve endings also express a variety of inhibitory neurotransmit-
ter receptors such as opioid, GABA, and cannabinoid receptors. These receptors 
are related to peripheral sensitization and they may be targets for analgesia drug 
development. Opioid is known as the most powerful drug for severe pain, including 
three classic opioid receptors in the central nervous system: μ-(MOR), δ-(DOR), 
and κ-(KOR) receptors [144]. The existence of the three receptors was confirmed 
by the identification and sequence analysis of complementary DNA and the selec-
tive deletion of opioid receptor genes [145]. In peripheral, opioid receptors are 
present on the peripheral terminals of thinly myelinated and unmyelinated cutane-
ous sensory fibers [138]. Opioid agonists can attenuate the excitability of primary 
afferent neurons and the release of proinflammatory neuropeptides from central 
and peripheral terminals. Particularly within injured tissue, these events lead to 
antinociceptive and anti-inflammatory effects [146].
All opioid receptors are members of the rhodopsin class of GPCR, principally, 
although not exclusively, mediating their effects via the Gi/o pertussis toxin (PTX)-
sensitive heterotrimeric G-protein family. After the ligand binds at the receptor, 
conformational changes allow intracellular coupling of mainly Gi/o proteins to 
the C-terminus of opioid receptors [147]. The μ-opioid agonists are still the gold 
standard for the treatment of moderate and severe pain. Agonists of μ-receptors 
exclusively coupled to inhibitory Gi/o proteins, which is important in anesthesia as 
they mediate the analgesic and sedative/hypnotic actions [148].
8.3.2 Opioids and pain
Both experimental and clinical studies suggest that peripheral analgesic effects 
of opioids are predominant under inflammatory conditions, leading to upregulation 
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of opioid receptors on peripheral sensory neurons and to local production of 
endogenous opioid peptides in immune cells [149–151]. The reason why opioids are 
predominantly functional under inflammatory conditions is that the opioid-pro-
ducing cells are recruited in the inflamed tissue but not non-inflamed tissue [152]. 
In models of peripheral inflammation, local injection of low, systemically inactive 
doses of μ, δ, and κ-receptor agonists produced analgesia which was dose-depen-
dent, stereospecific, and reversible by selective opioid antagonists [153]. In CFA-
induced paw inflammation, MOR mRNA displayed a biphasic upregulation (at 2 h 
and 96 h), whereas mRNA for DOR remained unchanged, and KOR mRNA showed 
a peak at 12 h [154, 155]. In addition, human studies indicated that local application 
of opioid agonists are beneficial in patients with visceral and neuropathic pain as 
these drugs have analgesic efficacy and less side-effects because they do not readily 
cross the blood-brain barrier [48, 156].
8.3.3 Opioid-induced hyperalgesia
Unexpectedly, a large number of studies have demonstrated that opioids can 
elicit hyperalgesia and allodynia [157]. Opioid-induced hyperalgesia (OIH) may 
be associated with analgesic tolerance. OIH refers usually to the development of 
hypersensitivity to painful stimuli observed upon chronic opioid administration. 
Different mechanisms have been identified for this process including sensitization 
of primary afferent neurons and enhanced release of glutamate by these primary 
afferents, hyperexcitability of second order neurons to excitatory neurotransmitters, 
and up-regulation of nociceptive neuromodulators by descending pain controls [158, 
159]. A lot of evidence suggests that MOR antagonists might reduce opioid analgesia 
[160]. However, the co-administration of methylnaltrexone bromide, a peripherally 
restricted MOR antagonist, was sufficient to abolish morphine tolerance and OIH 
without diminishing antinociception in perioperative and chronic pain models [161].
8.3.4 Other inhibitory receptors
Endogenous inhibitory receptors play a crucial part in the management of pain. 
Peripheral sensory neurons exhibit a large number of receptors that mediate inhibi-
tion of neuronal activity, and the agonists of these receptors produce antinociception. 
Application of either GABAA or GABAB receptor agonists attenuated the colonic affer-
ent response to colon stretch. Conversely, GABAA and GABAB receptor antagonists 
increased the stretch response. These results suggest that GABA receptors are present 
and functional in the peripheral terminals of colonic afferents, and activation of these 
receptors via endogenous GABA release contributes to the suppression of colonic 
afferent excitability and visceral nociception without the central nervous system 
[162]. The antinociceptive effects of cannabinoids were confirmed in preclinical mod-
els of inflammatory, cancer, and neuropathic pain and in several human studies [163]. 
In an animal electrophysiological model similar to our previous studies [164], soma-
tostatin inhibited the cross excitation between nerve terminals involved in peripheral 
hyperalgesia and had a peripheral analgesic effect [164]. The somatostatin and its 
receptors exerted a tonic inhibitory control over peripheral nociceptors, especially the 
peripheral nerve terminals of small-diameter cutaneous afferent fibers [165].
9. Conclusion
Based on the up-to-date studies in peripheral sensitization, we establish the 




this process, expecting to provide a new prospect of analgesics on peripheral targets 
in pain management. Noxious stimuli can excite the peripheral endings of primary 
sensory afferents, through activation of voltage-gated ion channels and/or ligand-
gated receptors that increase the number of action potentials, leading to peripheral 
sensitization. Many inflammation mediators and neurotransmitters participate in 
the peripheral sensitization. Therefore, these chemicals provide enormous options 
for pain intervention of peripheral origin. Topically administered drugs such as 
lidocaine and capsaicin in patches, capsaicin in cream, and creams containing anti-
depressants (i.e., doxepin and amitriptyline) act locally in tissues through specific 
receptors and/or ion channels [166]. Topical drug delivery focuses on peripheral 
mechanisms and not only reaches greater concentrations in the region where it is 
applied, but also produces fewer side-effects along with greatly enhanced efficacy. 
Considering the unspecific and multifaceted function of chemicals involved in the 
peripheral sensitization, it is crucial to select the most suitable and specific targets 
to treat certain pain disease in clinic.
Beyond the peripheral sensitization, changes in the central nervous system neu-
rons also play an essential role in the nociception process. Multiple lines of evidence 
show that central sensitization, produced following intense peripheral noxious 
stimuli, tissue injury, or nerve damage, is involved in diverse pain conditions, such as 
myofascial pain syndromes, idiopathic low back pain, and chronic pelvic pain [167]. 
Given the complexity and diversity of peripheral and central mechanisms of various 
pain conditions, it needs further investigation to figure out the specific mechanisms 
of pain symptoms and identify the most effective pain therapies in future.
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